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Lipid cubic phase formulations have gained recognition as potential controlled delivery systems for a
range of active pharmaceutical and biological agents on account of their desirable physiochemical prop-
erties and ability to encapsulate both hydrophobic and hydrophilic molecules. The most widely studied
lipid cubic systems are those of the monoacylglycerol lipid family. These formulations are susceptible to
lipolysis by a variety of enzymes, including lipases and esterases, which attack the ester bond present on
the lipid chain bridging the oleic acid component to the glycerol backbone. The release of poorly soluble
molecules residing in the lipid membrane portions of the phase is limited by the breakdown of the
matrix; thus, presenting a potential means for further controlling and sustaining the release of therapeu-
tic agents by targeting the matrix stability and its rate of degradation. The aims of the present study were
twofold: to evaluate an approach to regulate the rate of degradation of lipid cubic phase drug delivery
systems by targeting the enzyme interactions responsible for their demise; and to study the subsequent
drug release profiles from bulk lipid cubic gels using model drugs of contrasting hydrophobicity. Here,
hybrid materials consisting of cubic phases with monoacylglycerol lipids of different chain lengths for-
mulated with a potent lipase inhibitor tetrahydrolipstatin were designed. Modulation of the release of
M. Dully et al. / Journal of Colloid and Interface Science 573 (2020) 176–192 177a hydrophobic model pharmaceutical, a clofazimine salt, was obtained by exploiting the matrices’
enzyme-driven digestion. A stable cubic phase is described, displaying controlled degradation with at
least a 4-fold improvement compared to the blank systems shown in inhibitor-containing cubic systems.
Sustained release of the model hydrophobic pharmaceutical was studied over 30 days to highlight the
advantage of incorporating an inhibitor into the cubic network to achieve tunable lipid release systems.
This is done without negatively affecting the structure of the matrix itself, as shown by comprehensive
small-angle x-ray scattering experiments.
 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Challenges in the delivery of therapeutic agents in vivo include
controlling and maintaining their release at therapeutically effec-
tive doses over a sustained period of time, long enough for them
to exhibit their desired effect. Smart design of delivery systems
can help overcome these challenges. This is particularly applicable
in the design of delivery matrices for pharmaceuticals of poor
water solubility, which is believed to account for between 70 and
90% of new drugs in development [1,2]. Lipid carrier systems have
proven their potential in controlled delivery applications on
account of their unique microstructure and amphiphilic character,
as well as the biodegradable and biocompatible nature of the lipids
used [3,4]. Lipids, in different forms, have been widely utilized [5–
7]; from liposomes to lipid-derived nanoparticles [8,9] and both as
solid-state [10], and dispersed matrices [11,12].
One particular system, the lipid cubic phase, has generated
interest as a sustained delivery vehicle over the past two decades
[13]. These systems possess a unique microstructure [14–17] that
can be accessed under certain conditions of temperature and water
content [4,18], and have demonstrated their capacity to encapsu-
late and control the delivery of a wide range of pharmaceuticals
of different solubilities from enzymes and proteins to small mole-
cule drugs. Additionally, their inherent thermostability, even in
excess water, make the cubic phase and its dispersions attractive
vehicles for in vivo applications [19,20]. Lipid cubic phase formula-
tions have been used as transporters of both small molecules and
larger proteins through both oral [21,22] and parenteral routes as
well as in local delivery applications including subcutaneous and
intramuscular routes [13,23–25]. They have been utilized as sus-
tained release systems for a range of pharmaceutical agents of dif-
ferent aqueous solubilities [26–30], the majority of which
demonstrate diffusion-controlled release that follows first order
kinetics. Numerous commercially available host lipids
[3,14,28,31–33] capable of forming the cubic phase exist and the
selection of a suitable host is key in developing the cubic phase
for drug delivery applications.
The matrix’s application in sustained release, while proven to be
very promising, is somewhat limited as a consequence of its
shorter release profile which is often less than 24 h for hydrophilic
agents [13,28] and its highly viscous consistency which has been
likened to toothpaste [34]. Additionally, the integrity of monoacyl-
glycerol derived cubic phase (MAG LCPs) gels in particular are
greatly compromised by the presence of lipolytic enzymes
[28,35,36] – likely influencing the release kinetics of any
membrane-embedded hydrophobic drugs with which it is formu-
lated as has been described for numerous hydrogel systems [37].
These MAG lipid systems are subject to slow hydrolysis at the ester
linkage connecting the acyl chain (oleic acid) to the glycerol back-
bone [35,36,38]. The main perpetrators are a family of enzymes,
lipases, that are found in the body, often accompanied by other
offending abettors such as esterases. Lipases are water-soluble
and act at an oil-water interface during lipolysis of triglycerides
in any aqueous system through a series of intricate steps [35], with
the surface area being the rate limiting factor [36,39].The inhibition of lipase interactions through steric approaches
has previously been described as a means to impede the digestion
of lipid-based formulations for drug delivery [40–44]. Additionally,
a class of lipids exist that have been synthesized such that their
structure greatly resembles that of monoolein, except that the
glyceryl ester group is replaced by a glycerate [45]. As an alterna-
tive, here we present a novel chemical approach to achieve regu-
lated degradation and subsequent controlled drug release from
bulk lipid cubic systems by targeting these lipase enzyme interac-
tions through the incorporation of a known inhibitor into the lipid
network. The stability of two bulk LCP matrices is examined over
time in the presence of a hydrophilic or a hydrophobic active phar-
maceutical ingredient (API) and in the presence of tetrahydrolip-
statin (THL), a potent active site-directed lipase inhibitor [46–
50]. THL is FDA approved and indicated for the treatment of obesity
at concentrations that well exceed those used in this study [51]. A
surface loop system employed by pancreatic lipases controls access
to their active site. In the presence of lipid substrates and other
amphiphiles, the surface loop, or ‘lid’, undergoes a conformational
change thus exposing the enzyme’s catalytic site [52]. Upon expo-
sure, tetrahydrolipstatin exerts its inhibitory effect upon binding
the pancreatic lipase at its catalytic serine residue as it forms a
stable monolayer at the oil-water interface [42,53,54]. Following
a nucleophilic attack of the serine active site on the b-lactone
group [55,56], the THL forms a stoichiometric acyl-enzyme com-
plex with the various lipases [46,47,57] to impede the catalytic
degradation of the lipid formulation (Schematic displayed in the
supplementary information).
Lipolysis and its inhibition are considered to be a set of compet-
itive processes, often occurring simultaneously both in vitro and in
biological systems when an inhibitor and a lipid substrate co-exist
[58]. The efficacy and rate of the individual processes are dependent
on factors including concentration and surface area and are related
to the ratio of lipid substrate to enzyme inhibitor. The inhibitor
selected in this investigation was incorporated into the lipid cubic
gels at different concentrations in a bid to stabilize and control their
digestion by pancreatic lipase. A range of THL loadings from 0.35 to
2.5 wt% were selected to demonstrate the relationship between
inhibitor concentration and the rate of competitive lipolysis, subse-
quently allowing for the tunable degradation-driven release of
hydrophobicpharmaceuticals from their network.Within this range
of inhibitor concentrations, the cubic phase is accessed and main-
tained under the experimental conditions described in this investi-
gation, without any observed phase transition.
THL is practically insoluble in water [59] and so was expected to
reside mainly in the lipidic domain of the cubic phase, while its
hydrophilic portions may partition into the aqueous channel com-
partment. In a similar way that a lipid/water interface is necessary
for lipase catalysis, inhibition of the enzyme by THL is possible at
this boundary [39,53]. This means that most likely only the THL
available at the surface of the lipid network in the LCP can carry
out its inhibitory function while the THL integrated in the inner
bilayers would serve as a reservoir, reaching the lipid/water inter-
face upon the degradation of the gel [40,60,61]. This repository
provides fresh inhibitor to the system for the entirety of its life,
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exposes encapsulated THL to the lipolytic enzyme. A clofazimine
citrate salt and caffeine were selected as model APIs for release
studies based on their different propensities to dissolve in water
(~40 mg/L [62] and ~51 g/L [63] at 37 C for the CFZ-citrate and caf-
feine respectively). Their structures are shown in Fig. 1.
2. Material and methods
2.1. Materials
All solvents were analytical grade and purchased from FisherSci-
entific; Monoolein 9.9 MAG (1-(9Z-octadecenoyl)-rac-glycerol) and
Monopalmitolein 9.7 MAG (1-(9Z-hexadecenoyl)-rac-glycerol)
were acquired from JenaBioscience, Germany at > 99% purity; Phos-O
O
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Fig. 1. Chemical structures of: (a) monoolein (9.9 MAG) and (b) monopalmitolein (9.7
backbone; (c) lipase inhibitor tetrahydrolipstatin (THL); (d) hydrophobic model active phaphate buffered saline (PBS) tabletswere purchased fromMerk (Saint
Louis, MO);Water was purified in the lab using aMilli-QWater Sys-
tem (Millipore Corporation, Bedford,MA); Clofazimine (CAS registry
number 2030-63-9) was purchased from Beijing Mesochem Tech-
nology Co., Ltd. The clofazimine-citrate salt formwas produced pre-
viouslyby our group [62]; Lipase isolated fromporcinepancreaswas
purchased fromMerck,Germany (Type II, 100–500units/mgprotein
(using olive oil (30min incubation)), 30–90 units/mg protein (using
triacetin), L3126 SIGMA); Caffeine (99% purity, Sigma-Aldrich);
Tetrahydrolipstatin (Orlistat) (99% purity, Sigma-Aldrich).
2.2. Preparation of MAG LCP matrix formulations
Viscous lipid cubic phase formulations were obtained by dis-
pensing appropriate volumes of molten monoacylglycerol (MAG)O
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MAG) both possessing an ester linkage linking the oleic acid chain to the glycerol
rmaceutical ingredient (API) clofazimine-citrate; (e) hydrophilic model API caffeine.
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(MPL)  50 mg/sample) in glass vials. Fusion of dry MAG crystals
to the melt was achieved at 40 C. This was followed by the addi-
tion of the aqueous solution in excess volumes (45 wt%
and  55 wt% for MO and MPL LCP respectively) according to their
respective phase diagrams [18,32,64]. The samples were then sub-
jected to vortex mixing for at least 15 min and equilibrated and
stored in sealed glass vials out of direct light at room temperature
until an optically clear and visually homogenous sample was
achieved and for no longer than three weeks.
A range of MAG lipidic mixtures with 0.35, 0.7, 1.5 and 2.5 wt%
THL were prepared by first dissolving the inhibitor in the appropri-
ate weighed amounts of molten lipids. Homogeneous blends were
achieved by subjecting the molten solution to brief vortex mixing
with gentle heating. Mesophase samples were then generated by
mixing weighed quantities of MAG lipid-THL formulations with
Milli-Q water corresponding to ratios at excess hydration accord-
ing to the MAG lipid-water phase diagrams (40%  50% w/w).
The same approach was taken for the incorporation of the
hydrophobic API (CFZ-citrate salt) into the LCP whereby the API
crystals were dispersed in the molten MAG at the desired percent-
age weight before the introduction of water to the system to form
the cubic phase. For the hydrophilic API, caffeine, the caffeine was
dissolved in the water used to prepare the cubic phase and this was
added to the blank molten lipid. Both the caffeine and the CFZ-
citrate salt samples were prepared at concentrations of 1 and
3 wt% API.
2.3. Evaluation of MAG matrices
2.3.1. Polarizing light microscopy
Polarized light was utilized to assign the predicted liquid crys-
talline mesophase accessed. A spatula tip of the generated meso-
phase was transferred to a glass microscope slide and
immediately covered with a glass coverslip. The sample was exam-
ined under normal and cross polarized light at room temperature
on a Zeiss AxioScope Optical microscope equipped with polarized
light filter and a cross-polarizer. Image acquisition was carried
out using an AxioVision 4.8 imaging system by Carl Zeiss Ltd.
Non-birefringence in refraction was identified by the appearance
of a black image or zone on the camera.
2.4. SAXS
Small angle X-ray scattering was performed to confirm meso-
phase assignments for the formulations and to assign lattice
parameters.
2.4.1. SAXS sample preparation
Mesophase samples with discrete composition were prepared
as previously described for various concentrations of tetrahy-
drolipstatin within the range of 0 to 2.5 wt%. To study the metasta-
bility of the phases over a prolonged period of time, samples were
prepared 3 weeks, 4 days, 2 days and 1 h prior to SAXS data collec-
tion. Samples were stored in sealed vials until just before data
acquisition to avoid any sample dehydration through atmospheric
exposure. Another set of samples were tested to determine the
loading capabilities of the phase with the model APIs, prepared
as previously described at concentrations of 1 and 3 wt%.
2.4.2. SAXS data collection
SAXS measurements were carried out after sample preparation
at the Solution State SAXS B21 beam line at Diamond Light Source
on the Harwell Campus, Didcot, UK. The experiments used a beam
of wavelength k = 13.1 keV (~0.94644 Å) with a beam size at the
sample of 1 mm  1 mm. Data collection was performed at ambi-ent temperature (20 C). B21 utilizes a bending magnet source with
a typical flux of approximately 4  1012 photons per second deliv-
ered directly to the sample. The photons were distributed over a
large 0.8  2 mm cross-section which served to minimize radiation
damage while also enhancing the signal of the particles. 2D diffrac-
tion images were recorded on an Eiger X 4 M detector, with a
detector face size of 155.2 mm  162.5 mm and pixel size of
75 mm  75 mm. The beam size at the detector was
50 mm  50 mm. The detector was configured to measure a scatter-
ing vector (q) range from 0.0032 to 0.38 Å1. Samples were loaded
into a custom 3-D printed sample holder designed especially for
viscous samples. The holder was 3-D printed from a mixture of
methacrylic acid esters and photoinitiator comprising a window
in which the sample was filled. The sample holder was made from
stainless steel and had mica windows. Each sample was subjected
to a 1 s X-ray exposure for 15 frames at one location and required
manual loading.
2.4.3. SAXS data processing and analysis
Exposure of the lipid samples to the X-ray beam produced small
angle diffraction images. The detector images were azimuthally
reduced using DAWN, an eclipse-based workbench for carrying
out scientific data analysis [65] and subsequently analysed using
the lipidsaxs toolkit developed by Christopher Brasnett, University
of Bristol, available at https://github.com//csbrasnett/lipidsaxs.
The scattering intensity I (q) was represented as a function of the
magnitude of the scattering vector q = 4psinhk where 2h is the total
scattering angle.
2.5. Lipid cubic phase structural dimensions calculation
Taking into account the space group, lattice parameter and
water volume fraction of each of the different samples, the mono-
layer thickness and size of the water channels separating the lipid
framework was determined as outlined by Szlezak, Nieciecka [66]
and according to the following equations:
To compute the lipid volume fraction, first the water volume
fraction was calculated according to:
£aq ¼
caq
caq þ ð1 caqÞ qaqqMAG
  ð1Þ
where£aq is the volume fraction of the aqueous portion (0.386 and
0.496 for fully hydrated QDIIphaseofMO and MPL respectively. and
0.416 and 0.584 when the dehydrated QGII phase is seen for MO
and MPL respectively [64,67]), caq is the water weight fraction,
qaq denotes the density of water (0.997 g cm3), and qMAG repre-
sents the density of the MAG host lipid (0.942 g cm3 [68,69] for
monoolein and 0.982 g cm3 for monopalmitolein) [70].
By subtracting the water volume fraction from 1, the lipid vol-
ume fraction £MAG was determined [68]:
£MAG ¼ 1£aq ð2Þ
From there the lipid monolayer thickness (l) could be extrapo-
lated [70]:
£MAG ¼ 2Ao
l
d
 
þ 4
3pv ld
 3 ð3Þ
where Ao and the Euler characteristic v are constants specific to the
type of bicontinuous cubic phase related to the minimal surface
area given in Table 1, d is the lattice parameter determined by SAXS
for the phase in nm, and l is the lipid chain length or thickness of the
assembled lipid monolayer.
Ultimately, the radius of the congruent aqueous channels (raq)
within the network was estimated utilizing the calculated lipid
Table 1
Surface area constants [70,71].
Ao v
QDII 1.919 2
QPII 2.345 4
QGII 3.091 8
180 M. Dully et al. / Journal of Colloid and Interface Science 573 (2020) 176–192chain length according to the following equation based on minimal
surfaces [66,71]:
raq ¼
ffiffiffiffiffiffiffiffiffi
Ao
2pv
s !
d l ð4Þ
The area at the interface per lipid molecule in the unit cell of the
cubic phase (ai) was calculated directly according the following
[70]:
First, the lipid molecular volume (vMAG) was determined accord-
ing to [68]:
vMAG ¼
MWMAG
Avogadro0 s number
 
qMAG
ð5Þ
where MWMAG is the molecular weight (gmol1) for the host lipid,
taken as 356.6 and 328.5 gmol1 for MO and MPL respectively.
From there, the area at the interface per lipid molecule was esti-
mated according to the following equation:
ai ¼ 2vMAG ðAod
2 þ 2pvl2Þ
£MAGd
3 ð6Þ
where Aod
2 þ 2pvl2is equal to the area at the head group at the
interface integrated over a single monolayer
2.6. Enzyme stock preparation
A 5 mg/mL solution was prepared by dissolving the lipase in
0.1 M phosphate buffered saline (PBS), pH 7.4 ± 0.2. The prepara-
tion was carried out on ice to avoid denaturation or premature
activation of the enzyme. Enzyme solutions were stored on ice or
in the fridge and only used for up to one hour after preparation.
New solutions were prepared for experiments thereafter. It is
acknowledged that at this concentration, proteins displaying inter-
facial activity are prone to aggregation, however all samples were
treated identically in this investigation under the same experimen-
tal conditions of enzyme exposure.
For the clofazimine salt, ultrapure water was substituted for the
PBS in the preparation of the enzyme solution to prevent ion dis-
placement from the citrate salt form of the API leading to reduced
aqueous solubility [62].
2.7. Swelling and degradation behavior
To investigate the time-dependent swelling and degradation
behavior of the lipid cubic phase gels prepared with different com-
mercial lipids, pharmaceuticals and THL, dynamic swelling studies
were performed. After sufficient equilibration the gels were
weighed before submersion in 1 ml of phosphate buffered saline
solution (pH 7.4 ± 0.2), both in the presence and absence of
enzyme. The sample vials were tightly capped and maintained at
37 C. The samples were shaken at 200 rpm throughout the inves-
tigation to ensure homogenous exposure of the sample to the
enzyme. Porcine pancreatic lipase was selected for the study. For
the clofazimine salt, ultrapure water was again substituted forthe PBS to prevent ion displacement from the citrate salt form of
the API leading to reduced aqueous solubility [62].
The swelling and degradation ratios of the gels were studied by
means of a standard gravimetric method. The gels were removed
from the media at regular intervals and their liquid uptake and
mass loss was characterized by measuring the change in their
mass. The gels were rinsed with purified MilliQ water to remove
any residual salts potentially deposited on the surface of the gel
from the swelling media and lipase solution debris. The excess sur-
face water was then removed from samples by gentle blotting with
lint-free KimwipesTM before the samples were weighed on an ana-
lytical balance.
The swelling ratio and rate of degradation in terms of relative
weight % were calculated against the initial sample mass as per
the following equation:
Swelling Ratio or Residual Weight % ¼W1 W0
W0
 100% ð7Þ
where W0 is the initial gel weight before submersion in the media
and W1 is the weight of the gel at a measured time point after
immersion in the media.
2.8. Drug release studies
The release of the model pharmaceuticals CFZ-citrate and caf-
feine from the LCP was tracked at timed intervals for up to 31 days
in PBS or water for caffeine and CFZ-citrate respectively. Drug
release measurements consisted of removing the entire solution
from the sink and immediately replenishing it with fresh release
media. Throughout the measurement, the samples were shaken
at 200 rpm in an incubator at 37 C. The concentration of CFZ-
citrate and caffeine in the sink were measured by UV–vis spec-
trometry for CFZ-citrate and high performance liquid chromatogra-
phy (HPLC) for caffeine, due to interference from the lipids in
solution.
2.9. High performance liquid chromatography
The HPLC system used in this investigation was an Agilent 1200
Infinity Series (Agilent Technologies, Palo Alto, USA) comprising:
G1311B 1260 quaternary pump, G1329B 1260 ALS autosampler,
G1316A 1260 TCC (thermostated column compartment) and a
G1365D 1260 MWD VL diode-array detector. The acquired data
was processed with the Agilent OpenLAB CDS software.
Chromatographic separations of caffeine-containing samples
were achieved using an Agilent Poroshell 120 PFP (3  100 mm,
2.7 mm) column fitted with a UHPLC Poroshell 120 guard module
(3  5 mm, 2.7 mm). The system was maintained at 20 C with a
run time of 10 min. The mobile phase which comprised A: HPLC
Analytical grade Acetonitrile (Fisher Scientific) and B: deionized
water (A:B 15:85, v/v) was delivered to the column at a flow rate
of 0.64 ml/min which yielded a column back pressure of
~290 bar. Samples were filtered through a 0.2 mm nylon filter
(Fisherbrand) and 8 ml injections were made. UV detection was
conducted at a wavelength of 274 nm.
2.10. UV–visible spectroscopy
The concentration of CFZ citrate was determined by means of
UV–vis spectrophotometry. A full spectrumwas obtained on a dou-
ble beam UV-1800 Shimadzu UV–Visible spectrophotometer to
ascertain kmax for the drug, which was determined as 488 nm.
Absorbance values of release samples were then obtained with
appropriate dilution at this wavelength and Beer-Lambert’s Law
was then utilized to calculate the concentration of the API in the
sample.
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The release data obtained for the release of caffeine and clofaz-
imine citrate in the presence or absence of the THL inhibitor from
the twoMAG LCP formulations were treated according to a number
of release models: zero-order (cumulative % drug released v time
(min)); first order (Log cumulative % drug released v time (min));
Higuchi (cumulative % drug released v square root of time);
Hixson-Crowell (cube root % total drug - cube root of % unreleased
drug v time (min)); and Korsmeyer-Peppas (log cumulative % drug
released v log time) to obtain the correlation coefficient. The diffu-
sion coefficient (n) was estimated from the linear regression line of
the Korsmeyer-Peppas model for each sample.Fig. 2. 1D azimuthally integrated SAXS patterns of fresh monoolein (MO) and
Monopalmitolein (MPL) of blank cubic mesophases. The peaks of both patterns have
been indexed according to the QDII mesophase. Repetitions (see supplementary
information) demonstrated no impact on the mesophase from radiation damage.3. Results & discussion
3.1. Structural characterization of the mesophases
In this study, lipid cubic phases were successfully formed using
monoolein and monopalmitolein in the presence of hydrophobic
and hydrophilic pharmaceutical compounds as well as a lipase
inhibitor, the chemical structures of which are shown in Fig. 1.
Cubic phases are distinguishable by their discrete crystallographic
space groups. Three inverse bicontinuous cubic phases exist; prim-
itive (QPII), gyroid (Q
G
II ), and double-diamond (Q
D
II ) with symmetry
values of 229, 230, and 224 respectively. A range of characteriza-
tion techniques can be applied in the distinction of these phases.
This investigation utilized simple polarizing light microscopy and
more thorough small-angle X-ray scattering approaches to assign
mesophase properties to the test formulations. One can determine
whether a test material is anisotropic or isotropic in nature and
measure its birefringence simply by using cross-polarized micro-
scopy (CPLM) [72]. As the highly ordered cubic phase exhibits opti-
cal isotropy and its refraction is non-birefringent in nature, it gives
rise to a dark background between crossed polars as the phase is
essentially ‘invisible’ against the dark stage [73]. The lamellar
and hexagonal liquid crystalline phases on the other hand, are ani-
sotropic and optically birefringent thus split the plane of the inci-
dent light appearing as textured multi-coloured patterns. This
distinction allowed for the identification of the phases of our for-
mulations. Indeed, when the fresh formulations under investiga-
tion in this study were exposed to cross-polarized light, a dark
image was observed with no obvious signs of birefringence sug-
gesting a structure of cubic architecture.
While CPLM allows for differentiation between mesophases, its
usefulness is limited by an inability to distinguish between the var-
ious types of discrete cubic phases and it provides no means for
dimensional analysis. Small angle X-ray scattering investigations
enabled the lattice dimensions and unambiguous space group
symmetry to be assigned to each sample. They also allowed for
the effect of THL and API loading on the phase properties, and its
impact on the stability of the phase to be tracked. With a favorable
effect in terms of stability against lipolytic enzymes anticipated,
phase identification was required to confirm the loading capabili-
ties of the MAG LCP systems. Lipid cubic phases typically give rise
to diffraction patterns similar to those of powder X-ray diffraction;
characterized by a series of sharp, clearly defined concentric rings
owing to their randomly orientated domains of cubic symmetry
[10]. Fig. 2 shows the 1D azimuthally integrated SAXS patterns of
freshly made MAG LCP systems of MO and MPL. Bragg peaks have
been indexed according to the Miller indices of the reflection plane
to assign the mesophase. The relative positions of the reflection
lines indicated the presence of highly ordered bicontinuous cubic
phases in our samples. The MAG-water system typically accesses
two types of cubic phase under equilibrium at room and body tem-perature depending on the level of hydration [18]. At lower water
concentrations the gyroid or ‘QGII ’ cubic phase is accessed and
when hydration levels are increased the phase transitions to the
more swelled and stable diamond cubic (QDII ) phase. The Q
D
II phase
is stable against dilution and maintains its architecture when the
water content is increased further to excess levels. As expected,
in all of the systems for both host lipids, the phase in equilibrium
with excess water was of the cubic-QDII type with lattice parame-
ters (Table 2) slightly higher than those referenced in the literature
[74,75]. The estimated water channel diameter dimensions how-
ever (Table 2) were in agreement with published values [13,26]
with larger values for channel diameter estimated for the MPL sys-
tem as expected [67].
Samples prepared below excess hydration levels saw a transi-
tion from the QDII to Q
D
II + Q
G
II that occurred across all specimen,
even in those prepared fresh on the day of testing (data not
shown). In these dual-phase regions, the individual lattice param-
eter of the respective phases should remain constant with little
influence from the sample make-up as a whole. In Table 2, the
transition from a single phase to the co-existence of two bicontin-
uous cubic phases in the monoolein/water system is seen as dehy-
dration of the sample occurs [18,64], likely occurring during
transferal to the sample stage and also during storage [76]. It is also
possible that the fresh formulations had not yet fully equilibrated
to a homogeneous hydration state at the time of testing, which
could explain the coexistence of two cubic phases. The coexistence
between the QDII and Q
G
II is supported by the Bonnet ratio between
the lattice parameters: the ratio of unit cell dimensions of coexist-
ing cubic phases related through Bonnet transformations [77]. In
the case of coexistence between QDII and Q
G
II mesophases, the Bon-
net ratio should be 1.57. It should also be noted at this point, that
in utilizing X-rays for sample research, the impact of radiation
damage on any given specimen, especially those soft biomaterials
such as lipid mesophases, is a justified concern. However, the work
of Cherezov and colleagues attests that the radiation dosage and
exposure time used in this investigation is not likely to have a sig-
nificant impact on the MAG mesophases under examination [78].
Here, 15 frames per sample recorded sequentially in one single
location were analyzed and no significant difference was observed
in the series plots (supplementary information).
Table 2 reports the mesophases assigned for samples doped
with varying concentrations of THL, the lipase inhibitor, up to
2.5 wt% obtained from SAXS experiments using Eqs. (1) through
Table 2
Phase identification and lattice parameters of assigned mesophases at varied THL loadings from SAXS experiments with estimated dimensional values for lipid chain length (L)
and water channel diameter (DH2O). Samples assigned F were made fresh on the day of SAXS experiments.
Host Lipid THL (wt. %) Storage (days) mesophase Lattice Parameter (nm) L (nm) DH2O (nm) Bonnet ratio (where applicable)
MO 0 F QDII 10.17 1.74 4.48 –
MO 0 21 n/a* – – – –
MO 0.7 F QDII 9.92 1.69 4.37 –
MO 1.5 F QDII 9.6 1.64 4.23 –
MOCE 1.5 21
21
QDII
QGII
9.63
14.34
1.65
1.43
4.23
4.25
1.49
MO 2.5 F QDII 9.24 1.58 4.06 –
MPL 0 F QDII 10.8 1.48 5.48 –
MPL 0 21 n/a* – – – –
MPL 0.7 F QDII 10.47 1.43 5.32 –
MPL 1.5 F QDII 9.96 1.36 5.06 –
MPLCE 1.5 21
21
QDII
QGII
10.38
16.20
1.42
1.62
5.28
4.79
1.56
MPL 2.5 F QDII 9.88 1.35 5.03 –
CE Samples that presented the coexistence of two mesophases.
* One single peak detected i.e. no mesophase; storage time of sample in sealed vial prior to SAXS.
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tions of THL present cubic structures almost identical to those of
the blank matrices. Fig. 3 shows the effect of incorporating increas-
ing concentrations of the hydrophobic THL in MAG LCP systems of
MO and MPL on the SAXS patterns. The addition of the lipase inhi-
bitor appeared to bear no major effect on the peak positioning with
only minor shifts in scattering vector q observed. The integrated
SAXS patterns demonstrated how increasing the concentration of
the THL lipstatin saw a shift towards higher q for the LCP systems.
This is directly related to the swelling of the phase; with higher q
indicating a smaller lattice parameter of the mesophase. The lattice
spacing and space group assignment provide a metric for the esti-
mation of cubic phase structural dimensions, which can aid in host
lipid selection and loading capacity determination. The volume
fraction of the lipid component along with d-spacing values were
essential parameters in estimating the internal dimensions of the
mesophases [70]. Values pertaining to the structural dimensions
of the cubic formulations were estimated utilizing these parame-
ters as well as the phase identity obtained from the SAXS experi-
ments according to Eqs. (1) through (4). In bicontinuous cubic
phases, under conditions of equilibrium, the characteristic lattice
spacing is directly related to the diameter of its penetrating waterFig. 3. Azimuthally integrated SAXS patterns of monoolein (MO, a) and monopalmit
(fresh) – 2.5 w/w %. The patterns have been indexed according to the QDII mesophase.channels; and an increase in parameters is observed with increas-
ing hydration. This increase is seen only within certain limits [64].
In the case of the monoolein LCP system, the amount of the
hydrophobic THL added appeared to be inversely related to the
aqueous channel diameter; reducing by a little over 0.4 nm as
the weight percent of THL increased from 0 to 2.5% w/w, Table 2.
A decrease in water channel diameter is also evidenced by higher
q values as shown in Fig. 3. This coincided with a slight reduction
in lattice parameter for these samples. A similar relationship was
seen in the LCP systems prepared with the shorter chain
monopalmitolein host lipid whereby an increase in THL loading
saw a reduction in both the water channel diameter and lipid layer
depth. Indeed, the reduction in this case was slightly higher than
that in the MO 9.9 MAG monoolein system, with a reduction of
almost 0.5 nm observed.
The impact of THL on the stability of the LCP systems over time
was also investigated where the metastability of the phase struc-
ture over 3 weeks was studied. Diffraction patterns were examined
in relation to those samples freshly prepared on the day of testing.
A phase transition, similar to that observed in the samples pre-
pared below excess hydration, was seen in those samples stored
over a 3 week period when prepared with the inhibitor; whereolein (MPL, b) mesophases doped with increasing concentrations of THL from 0
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(QDII + Q
G
II ) was presented (Fig. 4(a) and (b)). However, in samples
prepared without the THL, the initial phase transitioned even fur-
ther beyond the liquid crystalline region entirely, highlighting the
stabilizing effect of the THL inhibitor on the LCP mesophase.
Smooth, sharp diffraction rings corresponding to discrete cubic
phase symmetry are highlighted in the 1D azimuthally integrated
SAXS patterns for the fresh samples in Fig. 4(a) and (b).
The observed increase in stability of the MAG LCP systems over
time owed to the presence of the inhibitor may be related to
changes in the packing frustration of the phases. When considering
the phase behavior of pure monoacylglycerols such as MO and
MPL, there are really only two major influential parameters at play
– temperature and water content. However, when you venture
outside of pure lipid systems and begin to consider how their
behavior is affected or driven by other compositional factors such
as the inclusion of additive molecules, one might find that the
phase behavior changes, potentially deviating from their classical
binary behavior. The impact of introducing a third contributing fac-
tor stretches the system beyond this simplistic model to a much
more complex ternary system [79]. The introduction of hydropho-
bic molecules in particular has been shown to induce changes on
the molecular level, subsequently altering the morphology of the
phase. These studies described the effect on packing frustration
(the energy cost associated with deviation from the favored shape
in a particular phase) of MO cubic phases induced by the addition
of a hydrophobic long chain alkane tricosane [80]. They have
demonstrated the relationship between the packing frustration
and cubic phase stability, whereby the introduction of the
hydrophobic molecules reduced the frustration by partitioning into
the hydrocarbon chain domains [81,82], subsequently stabilizing
the mesophase [83]. The stabilizing effect may also be explained
by an interaction between the hydrophilic moieties of the tetrahy-
drolipstatin molecule and the water present in the penetrating
channels. It is possible that hydrogen bonding between water
and the carbonyl or amide groups of THL, Fig. 1, could retain water
molecules in the matrix, thus maintaining the cubic phase over the
three week storage period investigated, where dehydration of the
blank systems resulted in the disassembly of the mesophase. More
thorough SAXS investigations into the exact location of the inhibi-
tor in the phase would be required to corroborate this theory.
Ultimately, the objective of this study was to control the rate of
release of hydrophobic drugs from LCP systems. To assess the suit-MO_T
Fig. 4. The effect of incorporating the hydrophobic THL lipstatin on the stability of mono
have been indexed according to the Miller indices of the reflection plane to assign mesoph
with 1.5 w/w % THL in order of decreasing storage time prior to analysis. The patterns hability of the THL-containing LCP systems as controlled drug deliv-
ery matrices, two model pharmaceutical agents (caffeine and CFZ-
citrate salt) were selected based on their propensity to dissolve in
water. Samples were prepared with increasing amounts of both
APIs (1 and 3 wt%) in a bid to establish the carrying capacity of
the cubic phase for APIs located in different regions of its network.
The resulting mesophases and their corresponding dimensional
estimations are shown in Table 3. As with samples without added
API, coexistence between QDIIand Q
G
IImesophases is supported by
the Bonnet ratio.
The incorporation of the hydrophobic CFZ citrate salt into the
lipid matrices lead to an increase in the lattice parameter, and
the width of the water channels. This effect was more pronounced
in the case of the upper loading of 3 wt% API. In the MPL system,
the coexistence of a second double diamond cubic phase structure
is observed with larger structure parameter values at both API
loadings (+0.91 to 1.32 Å). In the MO LCP-THL system, a phase
coexistence was observed, with reduced water channel diameter
and shift to higher q (Å) noted. The incorporation of hydrophilic
caffeine at 1 wt% loading into the MO LCP formulations did not sig-
nificantly affect the lattice parameter and size of water channels.
The relatively small size of the molecule (0.243 nm3) [84] meant
that it could be easily accommodated in the aqueous channels
(4.48 ± 0.03 and 5.48 ± 0.13 nm in MO and MPL LCP respectively,
shown as the mean value of 3 samples ± standard deviation) of
the matrix and therefore the QDII structure was preserved. The pres-
ence of the caffeine (1 wt%) in the 1.5 wt% THL LCP system left the
phase seemingly unaffected, with a single QDII space group main-
tained for both MO and MPL host lipid LCPs that were comparable
to the blank systems. It is clear that the structural parameters of
the QDII regions are greater than those of the Q
G
II . This is expected
as the QDII phase is accessed at a higher hydration point than the
QGII region, which in turn influences the physical dimension of
the unit cell [18,64]. The presence of an unassignable peak
between 0.134 and 0.136 Å1 in the MO samples containing the
caffeine API may be owed to API precipitation or formation of a caf-
feine hydrate in the system as the sharp Bragg peak was not
observed in the blank system and could not be assigned to any
mesophase. Its presence does however elude to the existence of a
crystal of some sort.
The release kinetics of the cubic phase are governed by the
phase identity and the capacity of its aqueous channels. In additionHL_1.5_FRESH MO_THL_1.5_3 WEEK
olein (a) and monopalmitolein (b) lipid systems over 3 weeks at 37 C. Bragg peaks
ase. 1D azimuthally integrated SAXS patterns of blank mesophases and those doped
ave been indexed to either the QDII (black text) or Q
G
II (red text) mesophase.
Table 3
Phase identification and lattice parameters of assigned mesophases for varied THL and model API loading from SAXS experiments with estimated dimensional values for lipid
chain length (L) and water channel diameter (DH2O).
Host Lipid THL (wt. %) API Storage (days) mesophase Lattice Parameter (nm) L (nm) DH2O (nm) Bonnet ratio (where applicable)
MOCE 0 CFZ 3% 2
2
QDII
QDII
10.74
9.55
1.83
1.63
4.73
4.21
–
MOCE 1.5 CFZ 1% 2
2
QDII
QGII
8.89
14.01
1.52
1.85
3.90
3.25
1.58
MPLCE 0 CFZ 1% 2
2
QDII
QDII
11.12
12.44
1.52
1.71
5.65
6.31
–
MPLCE 0 CFZ 3% 2
2
QDII
QDII
9.65
10.56
1.32
1.44
4.90
5.37
–
MPLCE 1.5 CFZ 1% 2
2
QDII
QDII
10.62
11.84
1.46
1.62
5.38
6.01
–
MO 0 Caff 1% 2 QDII 10.07 1.72 4.43 –
MO 0 Caff 3% 2 QGII 15.09 1.99 3.50 –
MO 1.5 Caff 1% 2 QDII 9.71 1.66 4.27 –
MPLCE 0 Caff 1% 2
2
QDII
QGII
11.75
18.11
1.61
1.81
5.96
5.36
1.54
MPLCE 0 Caff 3% 2
2
QDII
QGII
11.82
18.11
1.62
1.81
5.99
5.36
1.53
MPL 1.5 Caff 1% 2 QDII 10.46 1.43 5.32 –
*One single peak detected i.e. no mesophase; storage time of sample in sealed vial prior to SAXS.
CE Samples that presented the coexistence of two mesophases.
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have on the diffusion of the API, the properties of the API being
incorporated also influence the transport properties of the matrix
and have been reported to induce phase transformations upon for-
mulation [4,13,66]. It is therefore imperative to ensure that the
incorporated API does not disrupt the assembly of the cubic phase
lattice structure which may in turn affect its function. In some
cases, this may limit the use of the cubic phase as a drug delivery
matrix. While some dimensional changes in the crystallographic
unit cell were observed upon the incorporation of both model
drugs, the conclusion was drawn that the molecular distribution
of the lipid cubic phases was not significantly altered by their pres-
ence at concentrations below 3 wt%. Additionally, the incorpora-
tion of the lipase inhibitor THL did not induce a phase transition
and both systems have shown the ability to preserve the cubic
structures at room temperature; showing only a small increase of
the crystallographic unit cell parameter. This is important as major
changes in the phase properties, or transitions out of the cubic
region caused by the incorporation of an API, may render the sys-
tem unsuitable for certain applications as their release kinetics are
governed by the mesophase of the lipid delivery system.
3.2. Swelling and degradation
As previously discussed, the integrity of lipid cubic systems,
especially those generated from MAG host lipids, is vulnerable
in the presence of a family of enzymes referred to as lipases
[85]. This in turn may directly impact the release of the APIs
that it encapsulates. In humans three major lipases exist, where
their role is in the digestion and catabolism of dietary fatty
intake [54,86,87]. The lipase family of enzymes display signifi-
cant sequence homology between species and this investigation
utilized a model lipase from porcine pancreas to which tetrahy-
drolipstatin has the ability to bind and inhibit through irre-
versible interactions [88]. The lipolysis of the cubic phase in
solution was followed both visually and gravimetrically. At pre-
determined time points, the mass of the gel was measured and
the residual weight % was calculated (Eq. (7)). The degradation
could also be tracked visually, and its initiation was indicated
by the formation of an off-yellow oil layer on the outer surfaceof the gel. The digestion eventually resulted in an entirely cloudy
solution with the oily layer sitting on top.
For both MAG LCP systems, those exposed to lipolytic enzyme
in the incubation medium saw a rapid decline in original mass
for the blank MAG lipid cubic systems compared to those incu-
bated in enzyme-free PBS buffer. The integrity of the MO LCP
was compromised, and the enzyme action broke down the entire
gel after a 7 day exposure. The gel that was spared lipase exposure
maintained almost half of its original mass over a testing period of
12 days. Similarly, in the MPL LCP system, the gel maintained
94 ± 0.53% of its original mass after 17 days in the enzyme free buf-
fer, while the cubic gel exposed to lipase was digested to its oleic
acid and glycerol components over the course of 10 days. In fact,
the gel incubated in lipase-free buffer was subject to a loss of only
13 ± 2.5% over a testing period of 36 days.
Tetrahydrolipstatin is a potent lipase inhibitor and the lipophi-
lic molecule exerts its inhibitory effect upon binding the pancreatic
lipase at its serine active site as previously mentioned in the intro-
duction to this study. THL was incorporated into cubic formula-
tions generated from both host lipids at increasing
concentrations to study its effectiveness in impeding their lipoly-
sis. Concentrations of 0.35, 0.7, 1.5 and 2.5 wt% were chosen to
study the potential tunability of the systems in terms of the LCP
lifespan compared to the blank systems as a means of further con-
trolling the rate of release of hydrophobic APIs in particular, which
is concomitant with hydrolytic digestion.
Fig. 5 (a) shows the enzyme-driven hydrolysis of the monoolein
LCP gels, both with and without THL up to 2.5 wt% embedded in its
network. Increasing the concentration of the THL in the lipid net-
work incrementally decreased the degradation rate of the gels by
almost 6 fold at the highest loading compared to the LCP without
inhibitor. Even at the lowest inhibitor concentration (0.35 wt%),
the loss in original mass was slowed down and the systems main-
tained 49.7 ± 9.5% of their original mass after 7 days when the
blank LCP had been fully digested into their soluble oleic acid
and glycerol components.
A control group was also studied, where MO LCP was incubated
with lipase and free THL in solution at a concentration of 1.5 mg/
mL. Here, an increase in stability was observed as the samples were
fully degraded after 15 days compared to the degradation rate of
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Fig. 5. Swelling and degradation profile of: a) Monoolein and b) Monopalmitolein LCP formulations (Blank or formulated with THL) in Physiological Buffer (1X PBS) incubated
at 37 C in the presence of lipase enzyme. Each point represents a mean value ± standard deviation of three determinations.
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The rapid loss in mass may have occurred as a result of a combina-
tion of phase change and mass depletion rather than solely the
lipolysis of the lipid component itself. In this control group, the
THL in solution was replenished with each change of media at least
every 24 h, and yet the MO LCP with the THL incorporated into its
network displayed greater stability and did not fully degrade until
day 24. These latter samples only had the initial 1.5 mg/ml of THL
added for the duration the experiment and the depletion in mass
occurred with little initial swelling observed, possibly on account
of the hydrophobic effect of the membrane bound inhibitor point-
ing towards a predominantly surface-driven digestion pattern.
The same experimental conditions were tested on the MAG LCP
of slightly shorter chain length (just 2C shorter), monopalmitolein,
Fig. 5 (b). Once again, an increase in stability was noted in the pres-
ence of the THL, even at the lowest loading of 0.35 wt% where the
LCP samples maintained between ~31 and 33% of their original
mass at 10 days by when the blank gels were completely broken
down. There was no observed swelling between tested time-
points indicating that the diffusion of enzyme solution into thephase did not outpace the degradation. The 0.35 wt% samples were
not fully digested until after 15 days in incubation.
Both systems were considered to be comparable in terms of
tunable stability, and for the majority the error, while still rela-
tively small, between samples may be generally explained by the
variation in distribution of the lipstatin between gel formulations.
Although all samples were prepared following identical protocols
of manual and vortex mixing, the hydrophobic inhibitor is sus-
pended rather than dissolved within the formulation and is likely
not completely homogeneous. While the two LCP systems appear
to follow similar digestive trends, the incorporation of the THL
showed a more prolonged stability period in the MO LCP versus
the MPL system compared to the samples prepared without the
inhibitor in their respective profiles. This difference may be attrib-
uted to the difference in water channel diameters and lipid packing
described already in the SAXS section of this investigation, where
the wider diameter of aqueous channels in the MPL system
allowed for a higher penetration of the external lipase solution into
the phase’s aqueous network, in turn speeding up the degradation
process. The SAXS data clearly showed a lower degree of swelling
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(shown by higher q values) suggesting that lower volumes of lipase
solution could penetrate and diffuse into the phase.
The faster degradation of the MPL LCP system may therefore be
attributed to the higher surface area associated with the lipid por-
tion of the phase. The interfacial area per lipid molecule of both
MAG LCP systems was estimated using Eqs. (5,6) which utilized
the lattice parameter and calculated lipid chain length obtained
from the SAXS data. The calculated surface area was shown to be
larger in the shorter chain MPL system (Table 4). This provides
the lipase with a larger access area at the interface required for it
to carry out its lipolysis. On the contrary, the surface area is seen
to increase as the water channel diameter decreases with higher
THL loadings. Despite this, the degradation is clearly slowed down
by the THL’s presence which may seem counter-intuitive. It is
however hypothesized that with the larger associated surface area
of the lipid portion, comes greater inhibitor exposure at the inter-
face where lipase acts.
Once again, the digestion of the LCP samples was easily track-
able upon visual inspection. After prolonged lipase exposure, the
sample appearances became cloudier in colour, with a brittle core
covered in a more viscous outer layer. The samples prepared with
the inhibitor maintained the characteristically clear colour of the
lipid cubic phase for longer than those blank samples; with the
change in appearance noted after only 3 days in incubation for
the blank gels compared to 7 days in the doped gels.
To confirm that the THL-containing samples maintained the
cubic phase as well as the systemmass in the presence of the lipase
solution, LCP samples were prepared for both host lipid systems
with and without THL at 1.5 wt% incorporated into the membrane
and were exposed to lipase solution for 3 days before SAXS analysis
was conducted. In both cases, the QDII structure was preserved
despite a reduction in mass noted for the samples prepared in
the absence of THL (Table 5).
In the more readily digested MPL system in the absence of THL,
the SAXS data demonstrated a transition of the LCP to what
appears to be a hexagonal phase (HII) within the network afterTable 4
Calculated interfacial area per lipid molecule (ai) of MAG LCP generated at different THL l
Host Lipid THL % Storage (days
MO 0 F
MO 0.7 F
MO 1.5 F
MO 2.5 F
MPL 0 F
MPL 0.7 F
MPL 1.5 F
MPL 2.5 F
Table 5
Phase identification and lattice parameters of assigned mesophases for varied THL loading
Host Lipid THL (wt. %) Storage (days) Mesoph
MOCE 0 3 QDII
QDII
MO 1.5 3 QDII
MPLCE 0 3 QDII
HII
MPLCE 1.5 3 QDII
QDII
L is the lipid chain length/monolayer thickness (nm); DH20 is the diameter of the water
CE Samples that presented the coexistence of two mesophases; storage time of sampleexposure to the lipase. It is described in the literature that both
the instinctive formation of the phase and the thermodynamic sta-
bility of the LCP are driven by an opposition between a pair of free
energy terms. When this competition between the curvature
energy of the individual monolayers and stretching energy of the
lipid chains exists in its least frustrated state, it is suggested to
be responsible for the nature of the solid state phase and its posi-
tion on the phase diagram [71]. The hexagonal phase comprises an
arrangement of limitless water rods divided by lipid bilayers in a
two dimensional lattice and the transition to the phase upon lipase
interaction has previously been reported where the presence of the
lipase in solution served to increase the curvature of the system,
subsequently altering the molecular structure inducing a phase
transition [35,89]. This was not seen in the MO system although
the presence of a second QDII lattice was noted where only one
existed in the sample containing the inhibitor. The same phe-
nomenon was seen in the MPL system even in the sample formu-
lated with the inhibitor.
From the stability tests conducted in the presence of lipase, it
may be possible to control the duration of the prolonged release
of hydrophobic molecules from LCP matrix networks using lipase
inhibitors, allowing for the selection of the most suitable system
for a given clinical drug delivery application. Fig. 6 shows stability
plots for both of the LCP-inhibitor formulations; where increasing
THL concentration was plotted against the stability of the phase in
lipase solution. These models may provide researchers with a
mode of predicting the phase stability against lipase digestion up
to 40 or 36 days for the MO- and the MPL- THL LCP systems respec-
tively across a range of inhibitor concentrations from 0 to 2.5 wt%.
3.3. Drug release studies
Numerous approaches have been described to modulate the
kinetics of drug release to systematically control or prolong the
drug delivery period of hydrophilic agents [4,10,90–92]. In this
study, we sought to investigate the impact of addressing the rate
of degradation of the phase as a means to control the release ofoadings.
) mesophase ai (nm2)
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22
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22
QDII 3.75  10
22
exposed to lipase from SAXS experiments.
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Fig. 6. Stability plots for a) MO-THL and b) MPL-THL LCP-inhibitor systems showing
increasing THL concentration plotted against the stability (days) of the cubic phase
in lipase solution.
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hydrophobic pharmaceuticals. It was hypothesized that the incor-
poration of the inhibitor would have greater influence on the pre-
dicted degradation-driven release of hydrophobic agents and little
to no effect on more water-soluble molecules.
Clofazimine (CFZ), an antimycobacterial agent indicated for the
treatment of leprosy, was selected as a model drug on account of
its Biopharmaceuticals Classification System (BCS) class II proper-
ties of low aqueous solubility. Our group has previously developed
a number of novel salt forms of clofazimine in a bid to improve the
uptake of the drug in vivo [62]. One of these salts, co-formed with a
citrate ion, was selected for this study on account of its enhanced
aqueous solubility (~40 mg/L) which made studying its release
possible. Not only that, but the API itself has shown high uptake
in micelles and liposomes [93] and so its highly lipophilic nature
[94] render CFZ a perfect subject to profile the release of mem-
brane anchored molecules from our LCP-inhibitor systems.
The release of CFZ-citrate from the MAG systems, with and
without THL and in the presence of lipase at 37 C, is displayed
in Fig. 7. Upon initiation of significant digestion of the LCP matrices
after approximately 24 h in both systems in the absence of the
inhibitor, CFZ-citrate release appears to be inversely proportional
to the residual mass of the matrix. In the case of lipophilic APIs
such as CFZ citrate which are thought to be predominantly located
in the lipid bilayer, the rate of their diffusion is believed to be lim-
ited by their partitioning into the bilayers and is controlled by the
erosion and breakdown of the carrier [28]. The release of the CFZ
salt was found to be slower in the MO-based LCP compared to
the MPL system under identical conditions. This result was
expected from the faster degradation observed for MPL (Fig. 5) in
the absence of THL and presence of lipase, where the gel was
entirely digested into its core constituents. The oil layer main-
tained the characteristic red colour of the CFZ indicating that some
of the API remained bound to the lipid digestion products at the
end of the LCP gel degradation.The influence of THL on the dissolution profiles is also clearly
represented in Fig. 7 compared to the samples without the inhibi-
tor; showing the prolonged release of the hydrophobic model drug
upon its addition to the mesophases. The release rates were signif-
icantly slower in the systems that had the THL in their network
with less than 20% cumulative release in both host lipid formula-
tions after the testing period, indicating that its incorporation
can control the rate at which the drug is eliminated from the gels.
As discussed, this control is believed to be owed to the interaction
of the THL with the lipase, thus inhibiting the degradation of the
cubic mesophase. In the absence of the inhibitor, the lipase acts
at the lipid/water interface to breakdown the matrix into an oily
emulsion enabling the CFZ-citrate to partition into the media while
this effect is delayed by the presence of the THL.
In the MO system formulated with 1.5 wt% THL, the CFZ salt
continued to be released into solution at a steady rate over a 3 week
testing period. After a 21 day incubation at 37 C and 200 rpm
approximately 25% of the drug was released. 40% of the original
CFZ salt loading in the MPL-THL system was released from the bulk
phase after this period. The MO-based gel mass had not reduced
beyond 20% of its original weight and the MPL system maintained
almost 60% of its original mass after this time. These results high-
light the influence of tunable degradation of the cubic phase on
controlled release of hydrophobic agents.
The release data for these hydrophobic API systems was fitted
to a number of theoretical and empirical drug release models to
study the effect the incorporation of the inhibitor had on control-
ling the release of CFZ-citrate (supplementary information). The
literature indicates the Korsmeyers-Peppas, first-order kinetics
and Higuchi models as the most representative of release from
cubic phases [74]. These mathematical models, among others,
were applied. However, in this case, the release data did not appear
to fit well with these fundamental models described, although the
best fit was indeed seen with zero-order and Korsemeyer-Peppas
release kinetics indicating an anomalous non-Fickian diffusion
transport that is both diffusion and swelling/erosion controlled.
In examining the coefficient values (n) obtained for the CFZ salt
from the Korsemeyer-Peppas model, we saw values pointing
towards non-Fickian case 2 relaxation or super-case transport-2
mechanism (n > 0.45) on account of the hydrophobic salt’s location
in the lipid membrane. This supported the theory that erosion was
a driving force in its release [74]. In both cases, higher coefficient
values were observed in the gels without the inhibitor, where sig-
nificant degradation was observed over the testing period directly
related to the release of the drug into solution. These values elude
to deviation from straight-forward diffusive transport and the
results reiterate the influence the swelling and erosion of the
matrix has on release of CFZ and serves to further affirm the con-
cept of targeting degradation as a reasonable approach to extend
the control inherently offered by the cubic phase itself without
altering its phase structure.
While it is generally accepted that release of APIs from bio-
erodible polymers, such as lipid-based systems, is biphasic, driven
by both diffusion and matrix effect [37], it is clear from the model
plots and the respective r2 values obtained (supplementary infor-
mation) that the release from these LCP-inhibitor formulations is
not simplistic, nor two-dimensional. While these mathematical
models provided us with an indication of the release kinetics at
play, there are several influential factors in this ternary system that
drive the liberation of the hydrophobic API from its network. This
makes it difficult to apply the existing simplistic mathematical
models to its release, most of which assume a spherical-shaped
system, which of course is not this case here. The release profile
is, without dispute, complex with a combination/opposing effect
of the variables on water uptake and digestion responsible.
010
20
30
40
50
60
70
80
90
100
110
120
0
10
20
30
40
50
60
70
80
90
100
110
120
0 1 2 3 4 5 6 7 8 9 10
R
es
id
ua
l W
ei
gh
t %
C
um
ul
at
iv
e 
%
 A
PI
 R
el
ea
se
d
Time (days)
a)
MO_THL_CFZ
MO_CFZ
Residual Weight % MO_CFZ
Residual Weight % MO_THL_CFZ
0
10
20
30
40
50
60
70
80
90
100
110
120
130
0
10
20
30
40
50
60
70
80
90
100
110
120
130
0 1 2 3 4 5 6 7 8
R
es
id
ua
l W
ei
gh
t %
C
um
ul
at
iv
e 
%
 A
PI
 R
el
ea
se
d
Time (days)
b)
MPL_THL_CFZ
MPL_CFZ
Residual weight % MPL_THL_CFZ
Residual weight % MPL_CFZ
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within the matrix [37], it was expected that the dissolution of the
two model agents would follow different kinetics. To highlight the
influence of the APIs location within the matrix on its release pro-
file, caffeine was reconstituted in MAG LCP formulations to act as a
model hydrophilic agent and the effect of encapsulation with
lipase inhibitor THL on its release was studied. Release data was
obtained and quantified using HPLC. The dissolution profiles of
the hydrophilic model drug from these systems are shown in
Fig. 8, plotted with the degradation profiles of the matrices.
It was seen that the MO and MPL LCP systems were comparable
as far as the release of the caffeine is concerned, although a slightly
slower release was observed from the MO LCP system. The varia-
tions in release may once again be attributed to differences in
the water channel diameter of the two systems owing to an osmo-
tic effect; whereby different volumes of water can enter the
respective network of channels, and is related to the ratio of the
molecule size to water channel diameter [10]. It is obvious fromthe dissolution profiles of these formulations that the release of
caffeine was not greatly influenced by the introduction of THL into
MAG systems, as simple diffusive mechanisms were driving its
release and were largely independent of matrix effect. A decrease
in water channel diameter of almost 0.65 nm estimated in the
MPL-inhibitor system upon the addition of caffeine may account
for the slighter slower elution observed in the inhibitor system
[10]. The theories put forward by Clogston and Caffrey suggested
that as the size of the water channel approaches the size of the
molecule that it encapsulates, the diffusion of said molecule is slo-
wed or prevented. However, the narrower water channel diameter
in our systems still well exceeded that of the caffeine molecule,
even if it were to exist as a dimer or trimer and so explains the rel-
atively analogous release profiles with and without the THL inhibi-
tor. The SAXS data showed only minor reductions in water channel
diameter upon the addition of 1 wt% caffeine to the monoolein
LCP-inhibitor system evidenced in the largely comparable release
profiles with and without THL. However, the MO-THL samples
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blank MO-caffeine system despite a decrease in water channel
diameter of ~0.6 nm, which contradicts the aforementioned theory.
It is most likely explained by the fluid nature of the phase as it has
been suggested that the inherent flexibility of the liquid crystalline
phase may provide evolving fluid channels that facilitate the move-
ment of molecules through the network [10].
The release data collected from the caffeine system was also
treated against a number of mathematical models to obtain a cor-
relation coefficient (r2), which allowed for evaluation of the kinet-
ics of release of the hydrophilic model API from LCP. The more
simplistic release profile was seen to fit better with the linear mod-
els compared to the vastly complex elution behavior seen in the
CFZ salt model. The results (supplementary info) indicate that
the caffeine does indeed predominantly partition into the aqueous
channel network from which it diffuses into the media with little
influence from the digestion of the matrix itself. In contrast tothe kinetics of CFZ release, when the release data from the various
caffeine systems were fitted to the zero-order kinetic equation, the
relatively small regression values suggested that the system did
not obey the model. However, the dissolution results were found
to have a better fit with first order kinetics. The correlation coeffi-
cient in this case was closest to unity suggesting that the release of
caffeine from LCP most likely follows first order kinetics. This data
strongly confirms the expected diffusion-controlled kinetics. In
first-order release, the rate of drug diffusion is dependent on the
concentration of the API incorporated in the formulation.
Ultimately, this confirms the hypothesis that the incorporation
of THL would likely not affect the release kinetics of the hydrophi-
lic agent as its release is, for the most part, independent of the
breakdown of the matrix. For this reason, the system would be
suitable for a combined therapy application, whereby two or more
active agents with opposite solubility properties could be incorpo-
rated into the lipid system with the hydrophilic agent being
190 M. Dully et al. / Journal of Colloid and Interface Science 573 (2020) 176–192released within the first few days and more controlled, sustained
release of a hydrophobic agent could be achieved.
While this investigation focused primarily on an application
with bulk lipid cubic gels, there is recognizable scope to extend this
approach further to cubic nanodispersions. In this case, the inhibi-
tor may be encapsulated within the cubosomal network, either
pre- or post-fragmentation. The technique of controlling release
using inhibitors may be particularly appropriate for these formula-
tions, as cubic nanosystems are more readily degraded by enzymes
owing to their increased lipid-media interfacial area. The rate of
enzymatic digestion and the length of time required for these
nanoparticles to bind with, and be taken up through the cell mem-
brane will influence the release kinetics of an encapsulated drug.
Factors such as pH and enzyme concentration in the changing
environment of the cubosomes will also influence the release
kinetics. One may be interested in tailoring a system depending
on the proposed application. For example, a cubosomal-inhibitor
hybrid system may be attractive where overcoming the blood–
brain barrier is desired, as cubosomes have readily demonstrated
their ability to permeate this barrier [95,96]. Here the inhibitor
may serve to maintain the nanoparticle architecture for sufficient
time to allow successful transition across the barrier to deliver
the desired drug at the target site. Future work should focus on
exploring these influential factors to distinguish the dominating
parameters.4. Conclusions
The development of effective carrier systems that are capable of
delivering sustained and therapeutically relevant doses of drugs
has earned its place at the forefront of research over the last dec-
ade. The amphiphilic, biocompatible, and biodegradable nature of
the lipid cubic phase has merited the system as a worthy candidate
for controlled delivery. In this study, we have demonstrated that
controlled release of hydrophobic APIs can be achieved with a
novel formulation approach through the incorporation of small
doses of lipase inhibitors, using tetrahydralipstatin as a model.
Comprehensive SAXS experiments have shown, notwithstanding
some minor alterations in structural parameters, that the incorpo-
ration of the inhibitor bore no negative impact on the phase behav-
ior of our lipid cubic formulations below loading concentrations of
2.5 wt%.
The influence of hydrolytic enzymes on the stability of the cubic
phase has been widely demonstrated [35,36,38]. The true effect of
these enzymes responsible for catalyzing the hydrolysis of lipid
membranes was studied here to better predict the degradation rate
of the formulated LCP in vivo. Phase stability in the presence of
these enzymes was found to control the degradation-driven drug
elution. Through the incorporation of THL, the lipid vehicles have
demonstrated finely tunable rates of degradation that can be opti-
mally coordinated to release hydrophobic pharmaceutical, and bio-
logical molecules over a desired period of time before the gel
succumbs to complete digestion. Using CFZ citrate as a model drug,
the LCP-inhibitor systems could extend its release profile beyond
the one week duration in the blank LCP systems to weeks, and
potentially even months through interactions with the lipases
responsible for matrix digestion. These hybrid lipid cubic systems
may also provide means of delivering inhibitors to control the
action of these enzymes. Tetrahydralipstatin is a potent inhibitor
of many other lipolytic enzymes additional to the pancreatic lipase
studied here. These include gastric lipase, and carboxyl ester
lipases. Thus, the approach described here may have a more far-
reaching relevance. Should dosage requirements be defined and
applied in the formulation, our LCP-inhibitor system could poten-
tially be applied in a variety of drug administration routes withnumerous possible target delivery sites where different lipolytic
enzymes may be at play. Future work will delve further into the
intricacies of the interactions at play between the enzyme inhibitor
and the lipid ligand with the hydrolytic enzyme assisted by in silico
techniques, with an aim of understanding the, what we perceive to
be, competitive process. Furthermore, the possibility of applying
this technique to cubic dispersions for controlled delivery from
the nanosystems will be explored to demonstrate the reach of this
approach.
Funding sources
This work was financially supported by the Irish Research Coun-
cil under the Enterprise partnership scheme in association with
COOK Medical, Ireland.
CRediT authorship contribution statement
Michele Dully: Conceptualization, Methodology, Validation,
Formal analysis, Investigation, Writing - original draft, Visualiza-
tion, Funding acquisition, Data curation. Christopher Brasnett:
Resources, Writing - review & editing, Visualization, Formal analy-
sis. Ahmed Djeghader: Supervision. Annela Seddon: Writing -
review & editing, Supervision. John Neilan: Supervision, Resources.
David Murray: Supervision, Resources. James Butler: Supervision,
Resources. Tewfik Soulimane: Conceptualization, Resources, Writ-
ing - review & editing, Supervision, Project administration, Funding
acquisition. Sarah P. Hudson: Conceptualization, Resources, Writ-
ing - review & editing, Supervision, Project administration, Funding
acquisition.
Declaration of Competing Interest
The authors declare that they have no known competing finan-
cial interests or personal relationships that could have appeared
to influence the work reported in this paper.
Acknowledgment
We extend our thanks to Instrument Scientist Nikul Khunti and
all staff at Diamond Light Source, Didcot for facilitating the SAXS
experiments.
Appendix A. Supplementary material
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.jcis.2020.04.015.
References
[1] K. Vithani et al., Colloidal aspects of dispersion and digestion of self-dispersing
lipid-based formulations for poorly water-soluble drugs, Adv. Drug Deliv. Rev.
142 (2019) 16–34.
[2] M. Gigliobianco et al., Nanocrystals of poorly soluble drugs: Drug
bioavailability and physicochemical stability, Pharmaceutics 10 (3) (2018) 134.
[3] J. Barauskas, T. Landh, Phase behavior of the phytantriol/water system,
Langmuir 19 (23) (2003) 9562–9565.
[4] J. Clogston, Applications of the lepidic cubic phase: from controlled release and
uptake to in meso crystallization of membrane proteins, State University, The
Ohio, 2005.
[5] D.J. Hauss, Oral lipid-based formulations: enhancing the bioavailability of
poorly water-soluble drugs, CRC Press, 2007.
[6] R. Pandey, G. Khuller, Solid lipid particle-based inhalable sustained drug
delivery system against experimental tuberculosis, Tuberculosis 85 (4) (2005)
227–234.
[7] A. Samad, Y. Sultana, M. Aqil, Liposomal drug delivery systems: an update
review, Curr. Drug Deliv. 4 (4) (2007) 297–305.
[8] B. Angelov et al., Structural analysis of nanoparticulate carriers for
encapsulation of macromolecular drugs, J. Mol. Liq. 235 (2017) 83–89.
M. Dully et al. / Journal of Colloid and Interface Science 573 (2020) 176–192 191[9] A. Angelova, B. Angelov, Dual and multi-drug delivery nanoparticles towards
neuronal survival and synaptic repair, Neural Regener. Res. 12 (6) (2017) 886.
[10] J. Clogston, M. Caffrey, Controlling release from the lipidic cubic phase. Amino
acids, peptides, proteins and nucleic acids, J. Control. Release 107 (1) (2005)
97–111.
[11] A. S Duttagupta et al., Cubosomes: innovative nanostructures for drug delivery,
Current Drug Deliv. 13 (4) (2016) 482–493.
[12] K. Tilekar et al., Cubosomes - a drug delivery system, Int. J. Pharmaceutical,
Chem. Biol. Sci. 4 (4) (2014) 812–824.
[13] J.C. Shah, Y. Sadhale, D.M. Chilukuri, Cubic phase gels as drug delivery systems,
Adv. Drug Deliv. Rev. 47 (2–3) (2001) 229–250.
[14] P.-O. Eriksson, G. Lindblom, Lipid and water diffusion in bicontinuous cubic
phases measured by NMR, Biophys. J . 64 (1) (1993) 129–136.
[15] G. Lindblom, L. Rilfors, Cubic phases and isotropic structures formed by
membrane lipids—possible biological relevance, Biochimica et Biophysica Acta
(BBA)-Reviews on Biomembranes 988 (2) (1989) 221–256.
[16] E.M. Landau, J.P. Rosenbusch, Lipidic cubic phases: a novel concept for the
crystallization of membrane proteins, Proc. Natl. Acad. Sci. 93 (25) (1996)
14532–14535.
[17] V. Luzzati, F. Husson, The structure of the liquid-crystalline phases of lipid-
water systems, J. Cell Biol. 12 (2) (1962) 207–219.
[18] H. Qiu, M. Caffrey, The phase diagram of the monoolein/water system:
metastability and equilibrium aspects, Biomaterials 21 (3) (2000) 223–234.
[19] R. Forbes, A. Cooper, H. Mitchell, The composition of the adult human body as
determined by chemical analysis, J Biol Chem 203 (1) (1953) 359–366.
[20] S. Engström et al., A study of polar lipid drug systems undergoing a
thermoreversible lamellar-to-cubic phase transition, Int. J. Pharm. 86 (2–3)
(1992) 137–145.
[21] B.J. Boyd, Characterisation of drug release from cubosomes using the pressure
ultrafiltration method, Int. J. Pharm. 260 (2) (2003) 239–247.
[22] A. Angelova et al., Proteocubosomes: nanoporous vehicles with tertiary
organized fluid interfaces, Langmuir 21 (9) (2005) 4138–4143.
[23] A. Zabara et al., The nanoscience behind the art of in-meso crystallization of
membrane proteins, Nanoscale 9 (2) (2017) 754–763.
[24] J. Bender et al., Lipid cubic phases for improved topical drug delivery in
photodynamic therapy, J. Control. Release 106 (3) (2005) 350–360.
[25] L. Gan et al., Recent advances in topical ophthalmic drug delivery with lipid-
based nanocarriers, Drug Discov. Today 18 (5–6) (2013) 290–297.
[26] D. Wyatt, D. Dorschel, A cubic-phase delivery system composed of glyceryl
monooleate and water for sustained release of water-soluble drugs, Pharm.
Technol. 16 (10) (1992). 116-116.
[27] C.-M. Chang, R. Bodmeier, Effect of dissolution media and additives on the drug
release from cubic phase delivery systems, J. Control. Release 46 (3) (1997)
215–222.
[28] T. Norling et al., Formulation of a drug delivery system based on a mixture of
monoglycerides and triglycerides for use in the treatment of periodontal
disease, J. Clin. Periodontol. 19 (9) (1992) 687–692.
[29] R. Burrows, J. Collett, D. Attwood, The release of drugs from monoglyceride-
water liquid crystalline phases, Int. J. Pharm. 111 (3) (1994) 283–293.
[30] C.M. Chang, R. Bodmeier, Swelling of and drug release from monoglyceride-
based drug delivery systems, J. Pharm. Sci. 86 (6) (1997) 747–752.
[31] H. Chung, M. Caffrey, Polymorphism, mesomorphism, and metastability of
monoelaidin in excess water, Biophys. J. 69 (5) (1995) 1951–1963.
[32] J. Briggs, The phase behavior of hydrated monoacylglycerols and the design of
an X-ray compatible scanning calorimeter, Ths Ohio State University, 1994.
[33] M. Hato et al., Phase behavior of phytanyl-chained akylglycoside/water
systems, Trends Colloid Interface Sci. XVI (2004) 56–60.
[34] M. Caffrey, A comprehensive review of the lipid cubic phase or in meso
method for crystallizing membrane and soluble proteins and complexes, Acta
Crystallographica Section F: Struct. Biol. Commun. 71 (1) (2015) 3–18.
[35] J. Borné, T. Nylander, A. Khan, Effect of lipase on different lipid liquid
crystalline phases formed by oleic acid based acylglycerols in aqueous
systems, Langmuir 18 (23) (2002) 8972–8981.
[36] R. Wallin, T. Arnebrant, The activity of lipase at the cubic liquid-crystalline
phase/water interface, J. Colloid Interface Sci. 164 (1) (1994) 16–20.
[37] S. Fredenberg et al., The mechanisms of drug release in poly (lactic-co-glycolic
acid)-based drug delivery systems—a review, Int. J. Pharm. 415 (1–2) (2011)
34–52.
[38] J. Campos et al., On the interaction between adsorbed layers of monoolein and
the lipase action on the formed layers, Colloids Surf., B 26 (1–2) (2002) 172–182.
[39] R. Verger, G.H. De Haas, Interfacial enzyme kinetics of lipolysis, Ann. Rev.
Biophys. Bioeng. 5 (1) (1976) 77–117.
[40] M.H. Michaelsen et al., The effect of digestion and drug load on halofantrine
absorption from self-nanoemulsifying drug delivery system (SNEDDS), AAPS J.
18 (1) (2016) 180–186.
[41] O.M. Feeney et al., ‘Stealth’lipid-based formulations: poly (ethylene glycol)-
mediated digestion inhibition improves oral bioavailability of a model poorly
water soluble drug, J. Control. Release 192 (2014) 219–227.
[42] T. Tran et al., In vitro and in vivo performance of monoacyl phospholipid-based
self-emulsifying drug delivery systems, J. Control. Release 255 (2017) 45–53.
[43] Y. Li, D.J. McClements, Inhibition of lipase-catalyzed hydrolysis of emulsified
triglyceride oils by low-molecular weight surfactants under simulated
gastrointestinal conditions, Eur. J. Pharm. Biopharm. 79 (2) (2011) 423–431.
[44] M. Wulff-Pérez et al., Controlling lipolysis through steric surfactants: new
insights on the controlled degradation of submicron emulsions after oral and
intravenous administration, Int. J. Pharm. 423 (2) (2012) 161–166.[45] B.J. Boyd et al., Lyotropic liquid crystalline phases formed from glycerate
surfactants as sustained release drug delivery systems, Int. J. Pharm. 309 (1–2)
(2006) 218–226.
[46] P. Hadvary, H. Lengsfeld, H. Wolfer, Inhibition of pancreatic lipase in vitro
by the covalent inhibitor tetrahydrolipstatin, Biochem. J 256 (2) (1988)
357–361.
[47] Y. Gargouri et al., Inactivation of pancreatic and gastric lipases by THL and C12:
0-TNB: a kinetic study with emulsified tributyrin, Biochimica et Biophysica
Acta (BBA)-Lipids Lipid Metabol. 1085 (3) (1991) 322–328.
[48] A.M. Heck, J.A. Yanovski, K.A. Calis, Orlistat, a new lipase inhibitor for the
management of obesity, Pharmacotherapy: J. Human Pharmacol. Drug Therapy
20 (3) (2000) 270–279.
[49] M.L. Drent, E.A. van der Veen, First clinical studies with orlistat: a short review,
Obes. Res. 3 (S4) (1995) 623S–625S.
[50] M.W. Lee, F.B. Kraemer, D.L. Severson, Characterization of a partially purified
diacylglycerol lipase from bovine aorta, Biochimica et Biophysica Acta (BBA)-
Lipids Lipid Metabol. 1254 (3) (1995) 311–318.
[51] W. McNeely, P. Benfield, Orlistat, Drugs 56 (2) (1998) 241–249. discussion 250.
[52] F. Winkler, A. d’Arcy, W. Hunziker, Structure of human pancreatic lipase,
Nature 343 (6260) (1990) 771.
[53] A. Lookene, N. Skottova, G. Olivecrona, Interactions of lipoprotein lipase with
the active-site inhibitor tetrahydrolipstatin (Orlistat) R, Eur. J. Biochem. 222
(2) (1994) 395–403.
[54] D. Lawson, A. Brzozowski, G. Dodson, Lifting the lid off lipases, Curr. Biol 2
(1992) 473–475.
[55] P. Hadvary et al., The lipase inhibitor tetrahydrolipstatin binds covalently to
the putative active site serine of pancreatic lipase, J. Biol. Chem. 266 (4) (1991)
2021–2027.
[56] Q. Lüthi-Peng, H.P. Märki, P. Hadváry, Identification of the active-site serine in
human pancreatic lipase by chemical modification with tetrahydrolipstatin,
FEBS Lett. 299 (1) (1992) 111–115.
[57] B. Borgström, Mode of action of tetrahydrolipstatin: a derivative of the
naturally occurring lipase inhibitor lipstatin, Biochimica et Biophysica Acta
(BBA)-Lipids Lipid Metabol. 962 (3) (1988) 308–316.
[58] F. Carrière et al., Inhibition of gastrointestinal lipolysis by Orlistat during
digestion of test meals in healthy volunteers, Am. J. Physiol.-Gastrointestinal
Liver Physiol. 281 (1) (2001) G16–G28.
[59] Human Metabolome Database (HMDB). Orlistat. Available from: http://www.
hmdb.ca/metabolites/HMDB0015215.
[60] A. Tiss et al., Transfer of orlistat through oil–water interfaces, Chem. Phys.
Lipids 119 (1–2) (2002) 41–49.
[61] A. Tiss et al., Surface behaviour of bile salts and tetrahydrolipstatin at air/water
and oil/water interfaces, Chem. Phys. Lipids 111 (1) (2001) 73–85.
[62] P. Bannigan et al., Role of biorelevant dissolution media in the selection of
optimal Salt forms of oral drugs: maximizing the gastrointestinal solubility
and in vitro activity of the antimicrobial molecule, clofazimine, ACS Omega 2
(12) (2017) 8969–8981.
[63] F. Shakeel, W. Ramadan, Transdermal delivery of anticancer drug caffeine from
water-in-oil nanoemulsions, Colloids Surf., B 75 (1) (2010) 356–362.
[64] J. Briggs, H. Chung, M. Caffrey, The temperature-composition phase diagram
and mesophase structure characterization of the monoolein/water system, J.
Phys. II 6 (5) (1996) 723–751.
[65] J. Filik et al., Processing two-dimensional X-ray diffraction and small-angle
scattering data in DAWN 2, J. Appl. Crystallogr. 50 (3) (2017) 959–966.
[66] M. Szlezak et al., Monoolein cubic phase gels and cubosomes doped with
magnetic nanoparticles–hybrid materials for controlled drug release, ACS
Appl. Mater. Interfaces 9 (3) (2017) 2796–2805.
[67] X.E. Zhou et al., X-ray laser diffraction for structure determination of the
rhodopsin-arrestin complex, Sci. Data 3 (2016) 160021.
[68] C.V. Kulkarni et al., Monoolein: a magic lipid?, Phys Chem. Chem. Phys. 13 (8)
(2011) 3004–3021.
[69] A. Wade, P. Weller, Lactose, in: Handbook of Pharmaceutical Excipients, 2nd
ed., Pharmaceutical Press, London, 1994, pp. 252–261.
[70] D.C. Turner et al., Structural study of the inverted cubic phases of di-dodecyl
alkyl-b-D-glucopyranosyl-rac-glycerol, J. Phys. II 2 (11) (1992) 2039–2063.
[71] D.M. Anderson, S.M. Gruner, S. Leibler, Geometrical aspects of the frustration
in the cubic phases of lyotropic liquid crystals, Proc. Natl. Acad. Sci. 85 (15)
(1988) 5364–5368.
[72] R. Dombrowski, Microscopy techniques for analyzing the phase nature and
morphology of biomaterials, in: Characterization of Biomaterials, Elsevier,
2013, pp. 1–33.
[73] E. Lutton, Phase behavior of aqueous systems of monoglycerides, J. Am. Oil
Chem. Soc. 42 (12) (1965) 1068–1070.
[74] E. Nazaruk et al., Design and assembly of pH-sensitive lipidic cubic phase
matrices for drug release, Langmuir 30 (5) (2014) 1383–1390.
[75] F. Caboi et al., Structural effects, mobility, and redox behavior of vitamin K1
hosted in the monoolein/water liquid crystalline phases, Langmuir 13 (20)
(1997) 5476–5483.
[76] C.E. Conn et al., High-throughput analysis of the structural evolution of the
monoolein cubic phase in situ under crystallogenesis conditions, Soft Matter 8
(7) (2012) 2310–2321.
[77] B. Tenchov, R. Koynova, G. Rapp, Accelerated formation of cubic phases in
phosphatidylethanolamine dispersions, Biophys. J. 75 (2) (1998) 853–866.
[78] V. Cherezov, K.M. Riedl, M. Caffrey, Too hot to handle? Synchrotron X-ray
damage of lipid membranes and mesophases, J. Synchrotron Radiation 9 (6)
(2002) 333–341.
192 M. Dully et al. / Journal of Colloid and Interface Science 573 (2020) 176–192[79] L. van‘t Hag et al., Lyotropic liquid crystal engineering moving beyond binary
compositional space–ordered nanostructured amphiphile self-assembly
materials by design, Chem. Soc. Rev. 46 (10) (2017) 2705–2731.
[80] G.C. Shearman et al., Calculations of and evidence for chain packing stress in
inverse lyotropic bicontinuous cubic phases, Langmuir 23 (13) (2007) 7276–
7285.
[81] P. Duesing, R. Templer, J. Seddon, Quantifying packing frustration energy in
inverse lyotropic mesophases, Langmuir 13 (2) (1997) 351–359.
[82] R. Rand et al., Membrane curvature, lipid segregation, and structural
transitions for phospholipids under dual-solvent stress, Biochemistry 29 (1)
(1990) 76–87.
[83] R.H. Templer, B.J. Khoo, J.M. Seddon, Gaussian curvature modulus of an
amphiphilic monolayer, Langmuir 14 (26) (1998) 7427–7434.
[84] H.G. Edwards et al., Metamorphosis of caffeine hydrate and anhydrous
caffeine, J. Chem. Soc., Perkin Trans. 2 (10) (1997) 1985–1990.
[85] J.S. Patton et al., The light microscopy of triglyceride digestion, Food Struct. 4
(1) (1985) 5.
[86] T.G. Kirchgessner et al., Organization of the human lipoprotein lipase gene and
evolution of the lipase gene family, Proc. Natl. Acad. Sci. 86 (24) (1989) 9647–
9651.
[87] M. Mukherjee, Human digestive and metabolic lipases—a brief review, J. Mol.
Catal. B Enzym. 22 (5–6) (2003) 369–376.[88] D.B. Warren et al., Real time evolution of liquid crystalline nanostructure
during the digestion of formulation lipids using synchrotron small-angle X-ray
scattering, Langmuir 27 (15) (2011) 9528–9534.
[89] K. Larsson, Cubic lipid-water phases: structures and biomembrane aspects, J.
Phys. Chem. 93 (21) (1989) 7304–7314.
[90] M.L. Lynch et al., Enhanced loading of water-soluble actives into bicontinuous
cubic phase liquid crystals using cationic surfactants, J. Colloid Interface Sci.
260 (2) (2003) 404–413.
[91] K. Lindell et al., Influence of a charged phospholipid on the release pattern of
timolol maleate from cubic liquid crystalline phases, Colloid Sci. Lipids 108
(1998) 111–118.
[92] J. Clogston et al., Controlling release from the lipidic cubic phase by selective
alkylation, J. Control. Release 102 (2) (2005) 441–461.
[93] V. Patel, A. Misra, Encapsulation and stability of clofazimine liposomes, J.
Microencapsul. 16 (3) (1999) 357–367.
[94] J.R. O’Reilly, O.I. Corrigan, C.M. O’Driscoll, The effect of simple micellar systems
on the solubility and intestinal absorption of clofazimine (B663) in the
anaesthetised rat, Int. J. Pharm. 105 (2) (1994) 137–146.
[95] H. Azhari et al., Stabilising cubosomes with Tween 80 as a step towards
targeting lipid nanocarriers to the blood–brain barrier, Eur. J. Pharm.
Biopharm. 104 (2016) 148–155.
[96] H. Azhari, Surface modified cubosomes for drug delivery across the blood-
brain barrier, University of Otago, 2018.
